Nuvectis Pharma, Inc. NVCT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $18.58M+33.3% | $18.15M+40.5% | $17.56M+38.4% | $14.61M+1.8% | $13.94M-11.1% | ||
| $9.69M+36.8% | $9.42M+36.0% | $8.84M+16.7% | $8.36M+8.5% | $7.08M-5.8% | ||
| -$28.27M-34.5% | -$27.57M-38.9% | -$26.41M-30.3% | -$22.97M-4.1% | -$21.02M+9.4% | ||
| -$27.16M-34.7% | -$26.44M-39.2% | -$25.38M-31.0% | -$22.07M-4.6% | -$20.16M+9.9% | ||
| -$1.31-15.9% | -$1.32-18.9% | -$1.37-18.1% | -$1.17+9.3% | -$1.13+19.9% | ||
| -$1.31-15.9% | -$1.32-18.9% | -$1.37-18.1% | -$1.17+9.3% | -$1.13+19.9% | ||
| 89.3M+25.5% | 85.8M+26.6% | 81.1M+22.5% | 75.6M+16.2% | 71.2M+12.3% | ||
| 89.3M+25.5% | 85.8M+26.6% | 81.1M+22.5% | 75.6M+16.2% | 71.2M+12.3% | ||
| $1.11M+28.9% | $1.13M+33.6% | $1.03M+15.7% | $904K-5.9% | $858K+5.9% | ||
| -$28.27M-34.5% | -$27.57M-38.9% | -$26.41M-30.3% | -$22.97M-4.1% | -$21.02M+9.4% | ||
| -$28.27M-34.5% | -$27.57M-38.9% | -$26.41M-30.3% | -$22.97M-4.1% | -$21.02M+9.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Nuvectis Pharma, Inc. profitable?
- Nuvectis Pharma, Inc. is not currently profitable: it reported a net loss of $27.2M over the trailing twelve months.
- What is Nuvectis Pharma, Inc.'s earnings per share?
- Nuvectis Pharma, Inc.'s diluted EPS over the trailing twelve months is $-1.31.
- Where does Nuvectis Pharma, Inc.'s income statement data come from?
- Every line is extracted from Nuvectis Pharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.